beamion bcgc-1: a study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of her2+ cancer that has spread

Conditions: Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma

Summary: this study is open to adults aged 18 years and older with different types of her2+ cancer that has spread and cannot be removed by surgery. people can take part in this study if their tumours show her2 aberrations and previous treatment was not successful. the purpose of this study is to find a suitable dose of zongertinib that people with different types of her2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (t-dxd), with trastuzumab emtansine (t-dm1), or with trastuzumab and capecitabine. another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. zongertinib inhibits her2. her2 causes cancer cells to grow. in this study, participants receive treatment in cycles. study participants are treated with zongertinib alone or in combination with other treatments. this study has 2 parts. in part 1, participants in different groups receive increasing doses of zongertinib. in part 2, participants are put into different groups by chance. each group receives a different dose of zongertinib. every participant has an equal chance of being in each group. during the study, the participants visit the study site regularly. in this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with other treatments. to find this out, researchers look at certain severe health problems that a number of participants have. the doctors regularly check the size of the tumour with imaging methods (ct/mri) during the study. the doctors also regularly check participants' health and take note of any unwanted effects


Eligibility criteria:
inclusion criteria: * signed and dated written informed consent form (icf) in accordance with international council for harmonisation-good clinical practice (ich-gcp) and local legislation prior to admission to the trial. * patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the icf. * documented human epidermal growth factor receptor 2 overexpressing and/or amplified (her2+), metastatic breast cancer (mbc) or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma (mgeac). * for dose optimization (phase ii): patient must provide tumor tissue from locations not radiated prior to biopsy, if possible, collected through archival tissue. * documented investigator assessed progression. * recovered from any previous therapy-related toxicity to ≤ common terminology criteria for adverse events (ctcae) grade 1 at start of treatment (except for alopecia, stable sensory neuropathy, and hypothyroidism (patients on thyroid replacement therapy) which must be ≤ ctcae grade 2). * presence of at least one measurable lesion according to response evaluation criteria in solid tumors (recist) 1.1, as determined by the local site investigator/radiology assessment. * eastern cooperative oncology group (ecog) score of 0 or 1. further inclusion criteria apply. exclusion criteria: * previous or concomitant malignancies other than the one treated in this trial within the previous 2 years, which require current systemic therapy except: * effectively treated non-melanoma skin cancers * effectively treated carcinoma in situ of the cervix * effectively treated ductal carcinoma in situ * other effectively treated malignancy that is considered cured by local treatment * history or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure new york heart association (nyha) classification of ≥ iii or iv, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. myocardial infarction (or troponin levels consistent with myocardial infarction within 28 days of randomization), stroke, or pulmonary embolism within 6 months prior to randomization. * any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block. * mean resting corrected qt interval (qt interval corrected for heart rate by fridericia´s formula (qtcf)) \>470 msec. * any factors that increase the risk of qt interval corrected for heart rate (qtc) prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long qt syndrome, personal or family history of long qt syndrome or unexplained sudden death under 40 years-of-age. * ejection fraction \<50% or the lower limit of normal of the institutional standard within 28 days prior to randomization. * women who are pregnant or nursing or who plan to become pregnant or nurse during the trial or within 7 months after the last dose of trial treatment with t-dxd, t-dm1, trastuzumab or capecitabine and trastuzumab. further exclusion criteria apply.